Role of serotonin in the neurobiology of attention-deficit/hyperactivity disorder: a systematic literature review.

IF 4.4 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert Opinion on Therapeutic Targets Pub Date : 2025-09-01 Epub Date: 2025-09-03 DOI:10.1080/14728222.2025.2552324

Stephen V Faraone, Caroline L Ward, Matthieu Boucher, Reem Elbekai, Elizabeth Brunner

{"title":"Role of serotonin in the neurobiology of attention-deficit/hyperactivity disorder: a systematic literature review.","authors":"Stephen V Faraone, Caroline L Ward, Matthieu Boucher, Reem Elbekai, Elizabeth Brunner","doi":"10.1080/14728222.2025.2552324","DOIUrl":null,"url":null,"abstract":"Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a common neuropsychiatric disorder of inattention, hyperactivity, and impulsivity. Roles for dopamine and norepinephrine are widely recognized; however, the role of serotonergic neurotransmission is less clear. This systematic literature review aimed to determine if changes in serotonin transmission are implicated in the neurobiology of ADHD.Methods: A search of published literature was conducted. Eligible publications addressing the role of serotonin, its receptor family, and/or its transporter in the neurobiology of ADHD were selected according to prespecified criteria. The quality of evidence was graded.Results: Of 95 publications meeting our criteria, many (n = 60) were nonclinical studies. Most publications were rated as containing medium- (62.1%) or high-grade (17.9%) evidence. Multiple strands of evidence were found to implicate serotonin in ADHD, with 81.1% of the identified articles providing support for altered levels of serotonin production, binding, transport, or degradation in ADHD.Conclusions: Substantial evidence implicates serotonin in the neurobiology of ADHD and in the regulation of the catecholaminergic systems believed to be dysregulated by the disorder. Yet this evidence is incomplete and, at times, conflicting. It does suggest, however, that medications that engage the serotonin system should be tested for their efficacy in the treatment of ADHD.","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"637-654"},"PeriodicalIF":4.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728222.2025.2552324","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a common neuropsychiatric disorder of inattention, hyperactivity, and impulsivity. Roles for dopamine and norepinephrine are widely recognized; however, the role of serotonergic neurotransmission is less clear. This systematic literature review aimed to determine if changes in serotonin transmission are implicated in the neurobiology of ADHD.

Methods: A search of published literature was conducted. Eligible publications addressing the role of serotonin, its receptor family, and/or its transporter in the neurobiology of ADHD were selected according to prespecified criteria. The quality of evidence was graded.

Results: Of 95 publications meeting our criteria, many (n = 60) were nonclinical studies. Most publications were rated as containing medium- (62.1%) or high-grade (17.9%) evidence. Multiple strands of evidence were found to implicate serotonin in ADHD, with 81.1% of the identified articles providing support for altered levels of serotonin production, binding, transport, or degradation in ADHD.

Conclusions: Substantial evidence implicates serotonin in the neurobiology of ADHD and in the regulation of the catecholaminergic systems believed to be dysregulated by the disorder. Yet this evidence is incomplete and, at times, conflicting. It does suggest, however, that medications that engage the serotonin system should be tested for their efficacy in the treatment of ADHD.

查看原文本刊更多论文

5 -羟色胺在注意缺陷/多动障碍的神经生物学中的作用：系统的文献综述。

简介：注意力缺陷/多动障碍（ADHD）是一种常见的注意力不集中、多动和冲动的神经精神障碍。多巴胺和去甲肾上腺素的作用已得到广泛认可；然而，血清素能神经传递的作用尚不清楚。本系统文献综述旨在确定5 -羟色胺传递的变化是否与多动症的神经生物学有关。方法：检索已发表的文献。针对5 -羟色胺、其受体家族和/或其转运体在ADHD神经生物学中的作用的合格出版物是根据预先指定的标准选择的。证据的质量被分级。结果：在95篇符合我们标准的出版物中，许多（n = 60）是非临床研究。大多数出版物被评为含有中度（62.1%）或高级别（17.9%）证据。多种证据表明，5 -羟色胺与多动症有关，81.1%的已确认的文章支持ADHD中5 -羟色胺的产生、结合、运输或降解水平的改变。结论：大量证据表明，5 -羟色胺参与ADHD的神经生物学和儿茶酚胺能系统的调节，而儿茶酚胺能系统被认为是ADHD失调的原因。然而，这些证据是不完整的，有时还相互矛盾。然而，它确实表明，参与血清素系统的药物应该测试其治疗多动症的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Targets 医学-药学

CiteScore

8.90

自引率

1.70%

发文量

审稿时长

3 months

期刊介绍： The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.